Scynexis (SCYX) Operating Income (2013 - 2026)
Scynexis' (SCYX) quarterly Operating Income came in at -$16.9 million in Q1 2026, down 96.74% YoY from -$519.0 million in Q1 2025, and down 261.0% on a QoQ basis from $10.5 million in Q4 2025.
Scynexis (SCYX) Operating Income (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Operating Income data on file, last reported at -$16.9 million in Q1 2026.
- Quarterly Operating Income fell 96.74% year-over-year to -$16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.4 million (up 32.68% YoY) and the FY2025 annual result came in at -$16.1 million, up 56.69% from the prior year.
- Operating Income retreated to -$16.9 million in Q1 2026, from $10.5 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $116.5 million in Q2 2023 to a low of -$23.1 million in Q4 2023.
- A 5-year average of -$4.9 million and a median of -$10.1 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 1138.27% — and 2023, when it jumped 635.99%.
- Tracing SCYX's Operating Income over 5 years: stood at -$22.5 million in 2022, then dropped by 2.6% to -$23.1 million in 2023, then soared by 65.09% to -$8.1 million in 2024, then soared by 230.65% to $10.5 million in 2025, then slumped by 261.0% to -$16.9 million in 2026.
- The last three Operating Income figures came in at -$16.9 million (Q1 2026), $10.5 million (Q4 2025), and -$8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -7.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.78 Mn |
| Mar 31, 2026 | -16.94 Mn |
| Dec 31, 2025 | 10.52 Mn |
| Sep 30, 2025 | -8.41 Mn |
| Jun 30, 2025 | -9.56 Mn |
| Mar 31, 2025 | -8.61 Mn |
| Dec 31, 2024 | -8.05 Mn |
| Sep 30, 2024 | -10.32 Mn |
| Jun 30, 2024 | -9.24 Mn |
| Mar 31, 2024 | -9.51 Mn |
| Dec 31, 2023 | -23.07 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | 116.51 Mn |
| Mar 31, 2023 | -10.68 Mn |
| Dec 31, 2022 | -22.48 Mn |
| Sep 30, 2022 | -21.80 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | -19.74 Mn |
| Dec 31, 2021 | -22.30 Mn |
| Sep 30, 2021 | -19.44 Mn |